The FY21 Defense Appropriations Act is anticipated to provide funding for the Department of Defense Melanoma Research Program to support innovative, high-impact melanoma research.
A team of pancreatic cancer researchers was formed to predict which treatments might work best for individual pancreatic cancer patients based on the molecular traits of tumors.
A study by researchers at the UCLA Jonsson Comprehensive Cancer Center found that using percutaneous image guided needle based thermal ablation is a safe and effective adjunctive therapy for the local control of metastatic gynecologic cancers throughout lungs, liver, soft tissues in the abdomen and pelvis and bones—and in patients with advanced localized cancers unresponsive to systemic therapy.
Long-term, regular use of baby aspirin-at least 15 times per month-prior to a diagnosis of colorectal cancer may reduce the risk of death from the disease by limiting the spread of cancerous tumors pre-diagnosis, according to a study led by Cedars-Sinai Cancer researchers.
FDA has approved Abecma (idecabtagene vicleucel) for the treatment of adult patients with relapsed or refractory multiple myeloma after four or more prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody.
FDA has approved Sarclisa (isatuximab-irfc) in combination with carfilzomib and dexamethasone (Kd), for the treatment of adult patients with relapsed or refractory multiple myeloma who have received one to three prior lines of therapy.
Futibatinib (TAS-120), a covalently-binding FGFR inhibitor, has received Breakthrough Therapy designation from FDA for patients with previously treated locally advanced or metastatic cholangiocarcinoma harboring FGFR2 gene rearrangements, including gene fusions.
FDA has issued a Complete Response Letter regarding Merck’s supplemental Biologics License Application seeking approval for Keytruda, Merck’s company’s anti-PD-1 therapy, for the treatment of patients with high-risk early-stage triple-negative breast cancer, in combination with chemotherapy as neoadjuvant treatment, then continuing as a single agent as adjuvant (post-operative) treatment after surgery.
Huyabio International and Bristol-Myers Squibb Co. are planning to evaluate the combination of Huyabio’s HBI-8000, an epigenetic immunomodifier, and Opdivo (nivolumab), a PD-1 blocking antibody.
The European Commission has approved Cabometyx (cabozantinib) in combination Opdivo (nivolumab) for the first-line treatment of advanced renal cell carcinoma.
